Ultimovacs (OSE: ULTI)

Currency in NOK

Last close As at 25/09/2023

NOK79.90

−3.80 (−4.54%)

Market capitalisation

NOK2,748m

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare | Update

Ultimovacs — Gearing up for UV1 Phase II trial readouts

Healthcare | Flash note

Ultimovacs — FOCUS – first in series of upcoming catalysts

Healthcare | Flash note

Ultimovacs — Positive Phase I update in malignant melanoma

Healthcare | Update

Ultimovacs — UV1 by no means out after NIPU readout

Ultimovacs_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Carlos de Sousa

    CEO

  • Gustav Gaudernack

    CSO

  • Hans Vassgård Eid

    CFO

  • Jens Bjørheim

    CMO

  • Ton Berkien

    CBO

Balance Sheet

Forecast net cash (NOKm)

346.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 9.6 5.1 30.8
Relative 5.5 (3.4) 19.6
52 week high/low NOK136.0/NOK59.9

Financials

Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset, UV1, activates the immune system to recognise cancer cells that express hTERT, which is present in c 85% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total. Readouts are expected over 2023–25. The most near-term catalyst for the share price is topline readouts from the Phase II INITIUM study in malignant melanoma, expected in H124.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2021A 0.0 (161.1) (164.7) (508.83) N/A N/A
2022A 0.0 (181.0) (167.8) (489.06) N/A N/A
2023E 0.0 (235.8) (214.8) (624.46) N/A N/A
2024E 0.0 (274.0) (277.9) (807.84) N/A N/A

Research

edison tv

Healthcare

Ultimovacs – executive interview

Flash note

Healthcare

Ultimovacs — Further positivity for UV1

Update

Healthcare

Ultimovacs — UV1 development funded past key readouts

Flash note

Healthcare

Ultimovacs — Patient expansion in Phase I TENDU

Flash note

Healthcare

Ultimovacs — Positive Phase I survival data in melanoma

Flash note

Healthcare

Ultimovacs — UV1 Phase II data flow creeps closer

edison tv

Healthcare

Ultimovacs – executive interview

Update

Healthcare

Ultimovacs — New large indication for UV1

edison tv

Healthcare

Ultimovacs – Edison Open House interview

QuickView

Healthcare

Ultimovacs — Phase II data from 500+ patients over 2022/23

QuickView

Healthcare

Ultimovacs — Cancer vaccine with near-universal potential

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

ASX Spotlight Conference – London, 6 March 2014

thematic

Healthcare

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?